The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori

Helicobacter pylori eradication has substantially reduced the incidence of gastric cancer and is now a cornerstone of gastric cancer prevention. However, the risk of gastric cancer persists even after successful eradication, and post-eradication gastric cancer has become an increasingly important clinical challenge. Recent epidemiological studies have suggested that long-term use of potent acid suppressants, including proton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs), may further increase this residual risk, although findings have been inconsistent across studies. Following eradication, recovery of gastric acid secretion frequently precipitates gastroesophageal reflux symptoms, often leading to prolonged PPI or PCAB therapy, although the overall impact of eradication on the risk of gastroesophageal reflux disease remains uncertain. Some of the large-scale observational studies have demonstrated an association between long-term acid suppressant use and an increased risk of gastric cancer, with evidence of dose- and duration-dependent effects. Although causality has not been established, several biological mechanisms have been proposed. Sustained acid suppression induces hypergastrinemia, which may influence gastric epithelial proliferation and stem/progenitor cell dynamics mainly in the gastric corpus, although its effects appear to vary depending on the gastric region and cellular context. In addition, elevation of gastric pH alters the gastric microbiota, resulting in dysbiosis characterized by enrichment of potentially carcinogenic bacteria, chronic low-grade inflammation, and increased production of genotoxic metabolites. These mechanisms may act synergistically to facilitate gastric carcinogenesis in the post-eradication stomach. Given the accumulating evidence, long-term PPI or PCAB therapy should be prescribed only when clinically indicated, using the lowest effective dose and shortest possible duration. In patients requiring prolonged acid suppression, careful risk assessment and appropriate endoscopic surveillance should be considered. Further prospective studies are needed to clarify the causal relationship between acid suppressants and post-eradication gastric cancer.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-17
DOI
https://doi.org/10.3390/jcm15229000
Primary Topic
Helicobacter pylori-related gastroenterology studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori

Junya Arai, Yoku Hayakawa, Hiroaki Fujiwara, Masato Kasuga
Journal of Clinical Medicine
Helicobacter pylori-related gastroenterology studies
article

The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori

Junya Arai, Yoku Hayakawa, Hiroaki Fujiwara, Masato Kasuga
article en

Abstract

Helicobacter pylori eradication has substantially reduced the incidence of gastric cancer and is now a cornerstone of gastric cancer prevention. However, the risk of gastric cancer persists even after successful eradication, and post-eradication gastric cancer has become an increasingly important clinical challenge. Recent epidemiological studies have suggested that long-term use of potent acid suppressants, including proton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs), may further increase this residual risk, although findings have been inconsistent across studies. Following eradication, recovery of gastric acid secretion frequently precipitates gastroesophageal reflux symptoms, often leading to prolonged PPI or PCAB therapy, although the overall impact of eradication on the risk of gastroesophageal reflux disease remains uncertain. Some of the large-scale observational studies have demonstrated an association between long-term acid suppressant use and an increased risk of gastric cancer, with evidence of dose- and duration-dependent effects. Although causality has not been established, several biological mechanisms have been proposed. Sustained acid suppression induces hypergastrinemia, which may influence gastric epithelial proliferation and stem/progenitor cell dynamics mainly in the gastric corpus, although its effects appear to vary depending on the gastric region and cellular context. In addition, elevation of gastric pH alters the gastric microbiota, resulting in dysbiosis characterized by enrichment of potentially carcinogenic bacteria, chronic low-grade inflammation, and increased production of genotoxic metabolites. These mechanisms may act synergistically to facilitate gastric carcinogenesis in the post-eradication stomach. Given the accumulating evidence, long-term PPI or PCAB therapy should be prescribed only when clinically indicated, using the lowest effective dose and shortest possible duration. In patients requiring prolonged acid suppression, careful risk assessment and appropriate endoscopic surveillance should be considered. Further prospective studies are needed to clarify the causal relationship between acid suppressants and post-eradication gastric cancer.

Journal of Clinical MedicineVol. 15(22)
The Institute of Medical Science, Asahi Life Foundation (JP), The University of Tokyo (JP)
Helicobacter pylori-related gastroenterology studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon